UL Solutions’s (NYSE:ULS) Q2 CY2026 Earnings Results: Revenue In Line With Expectations

UL Solutions (NYSE:ULS) reported Q2 CY2026 results. Revenue rose 5.2% year on year to $816 million, in line with Wall Street expectations, and non-GAAP EPS was $0.59, 5.4% above consensus. Adjusted operating margin was 21.2% and free cash flow was $91 million. The stock was flat at $91.61 after the release.

Original reporting
Published Aug 4, 2026, 12:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 12:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UL Solutions’s (NYSE:ULS) Q2 CY2026 Earnings Results: Revenue In Line With Expectations — source image
Decision brief

The 30-second read

$ULSNeutralMed
01

Why it matters

The key tradable elements are the in-line revenue, the non-GAAP EPS beat, the adjusted operating margin expansion, and the decelerating forward revenue growth expectation.

02

Market read

This is a single-company earnings update with mixed signals: modest profitability improvement and EPS beat, but forward revenue growth expectations decelerate and cash conversion softened YoY.

03

What to watch

Free cash flow margin fell 2.4 percentage points YoY in Q2, which could offset the operating margin improvement if investors prioritize cash conversion.

Relevance 7/10Novelty 6/10Timing: post-earnings, same-day reaction described as stock flat at $91.61

Background

UL Solutions is a testing, inspection, and certification provider, and the article frames Q2 results versus consensus and discusses profitability and cash flow trends.

Company-level read

Ticker impact

$ULSNeutralMedium confidence
Context

UL Solutions reported Q2 CY2026 revenue of $816 million, up 5.2% YoY and in line with Wall Street estimates.

Expected impact

Near-term reaction likely muted unless investors extrapolate margin expansion and cash flow stabilization into forward estimates.

Evidence & confidence

The article provides a concrete earnings datapoint (revenue in line, EPS beat) and notes adjusted operating margin improvement, but it also flags forward revenue growth expectations of 4.9% as decelerating.

Market effects

Provides a datapoint on business-services safety certification demand and profitability trend, but no sector-wide catalyst is disclosed.

No regional demand or macro linkage is specified beyond general Wall Street expectations.

No international regulatory or global contract developments are mentioned.

Counterpoint

The revenue print is explicitly “in line,” so the market may treat the EPS beat as insufficient to re-rate the stock without stronger forward growth.

Key entities

  • UL Solutions

    Reported Q2 CY2026 revenue and non-GAAP EPS, plus margin and free cash flow metrics, and discussed forward revenue growth expectations.

Related articles

$ULSHigh

UL Solutions Inc. (ULS): Results of Operations and Financial Condition

UL Solutions Inc. (ULS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026ulsolution.htm EX-99.1 Document Exhibit 99.1 UL Solutions Inc. Reports Strong Second Quarter 2026 Results Second Quarter 2026 1 • Strong revenue growth of 5.2% to $816 million, including 6.6% organic revenue growth • Net income of $254 million increased

$LLYMedAI 8/10

Eli Lilly and Company Q2 Earnings Call Highlights

Eli Lilly (LLY) reported Q2 U.S. revenue up 33% led by ZEPBOUND and MOUNJARO volume, while U.S. price fell 3% (9% excluding rebate and discount estimate changes). International revenue rose in constant currency, with MOUNJARO a key driver. Lilly raised its 2026 revenue outlook to $85B-$87B and guided non-GAAP EPS $35.50-$36.50. It also discussed Medicare GLP-1 coverage expansion and retatrutide Phase III results.

$BRK-BMed

Berkshire Hathaway Just Did Something It Hasn’t Done in More Than 3 Years

Berkshire Hathaway reported Q2 2026 cash and Treasury bills of $365.5 billion, down from $397.4 billion in Q1, ending a 14-quarter streak as a net seller. According to Berkshire, CEO Greg Abel became a net buyer of equities, adding about $20 billion net, and increased buybacks to $4.5 billion. Apple fell to 20% of the portfolio; Alphabet rose after a $10 billion investment.

$LIONMed

Lionsgate Studios Q1 Earnings Call Highlights

Lionsgate (NYSE:LION) Q1 earnings call said it expects downstream revenue from films through fiscal 2027 and that The Hunger Games: Sunrise on the Reaping could support later-year results. Television revenue was $189 million, segment profit $10 million. Trailing 12-month library revenue was $987 million, backlog $1.5 billion. Net debt fell $121 million to about $1.5 billion; leverage improved to 4.3x.

$ENBMed

Enbridge Delivers Strong Q2 Results: Is the Stock Still a Buy?

Enbridge reported Q2 2026 results, with adjusted earnings of $1.4B, or $0.63 per share, roughly matching last year’s $0.65. Adjusted EBITDA rose to $4.8B from $4.6B. Operating cash flow increased to $4.1B from $3.2B. The company reaffirmed full-year guidance, added $1B to a $41B growth backlog, sanctioned Line 5 relocation and signed an option for the TTC Connector Pipeline.